<?xml version='1.0' encoding='utf-8'?>
<document id="23737453"><sentence text="Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects." /><sentence text="Almorexant is the first representative of the new class of orexin receptor antagonists, which could become a new treatment option for insomnia" /><sentence text=" The present study investigated the potential interaction between almorexant and warfarin" /><sentence text="" /><sentence text="In this open-label, two-way crossover, drug-drug interaction study, healthy male subjects received, in a randomized fashion, almorexant 200 mg once daily for 10 days and a single dose of 25 mg warfarin co-administered on day 5 (treatment A) and a single dose of 25 mg warfarin on day 1 (treatment B)" /><sentence text=" Serial blood samples for warfarin pharmacokinetics and pharmacodynamics were drawn during both treatments" /><sentence text="" /><sentence text="Of the 14 enrolled subjects, one withdrew due to an adverse event and 13 completed the study" /><sentence text=" Almorexant had no effect on the pharmacokinetics of warfarin"><entity charOffset="53-61" id="DDI-PubMed.23737453.s9.e0" text="warfarin" /></sentence><sentence text=" The geometric mean ratios (90% confidence interval) for the area under the plasma concentration-time curve to infinity (AUC0-âˆž) of S- and R-warfarin were 0" /><sentence text="99 (0" /><sentence text="89, 1" /><sentence text="09) and 1" /><sentence text="05 (0" /><sentence text="95, 1" /><sentence text="16), respectively, and for the maximum plasma concentration (Cmax) were 0" /><sentence text="99 (0" /><sentence text="86, 1" /><sentence text="14) and 1" /><sentence text="00 (0" /><sentence text="88, 1" /><sentence text="13), respectively" /><sentence text=" The main pharmacodynamic variable was the AUC for the international normalized ratio (AUCINR)" /><sentence text=" Almorexant had no effect on this variable as demonstrated by a geometric mean ratio of 0" /><sentence text="99 (0" /><sentence text="82, 1" /><sentence text="19)" /><sentence text=" Secondary pharmacodynamic variables including maximum effect (Emax), the time to the maximum INR, and factor VII plasma concentrations were also not affected by almorexant" /><sentence text="" /><sentence text="No dose adjustment of warfarin is necessary when concomitantly administered with almorexant"><entity charOffset="22-30" id="DDI-PubMed.23737453.s30.e0" text="warfarin" /></sentence><sentence text="" /></document>